US Stock MarketDetailed Quotes

BMY Bristol-Myers Squibb

Watchlist
  • 58.310
  • +1.510+2.66%
Trading Nov 19 13:31 ET
118.26BMarket Cap-16287P/E (TTM)

Bristol-Myers Squibb Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
17.68%5.59B
23.26%2.33B
-4.58%2.83B
6.08%13.86B
28.61%4.25B
28.86%4.75B
-16.54%1.89B
-22.09%2.97B
-19.38%13.07B
-18.51%3.31B
Net income from continuing operations
-37.18%1.22B
-18.92%1.68B
-625.28%-11.91B
26.71%8.04B
-12.99%1.76B
20.27%1.93B
45.35%2.08B
76.70%2.27B
-9.54%6.35B
-14.63%2.03B
Operating gains losses
-35.14%-300M
-128.48%-377M
-879.49%-382M
-176.34%-724M
26.96%-298M
-14.43%-222M
-298.80%-165M
-115.18%-39M
81.67%-262M
-265.18%-408M
Depreciation and amortization
6.45%2.59B
6.74%2.6B
4.24%2.53B
-5.02%9.76B
-2.26%2.46B
-5.91%2.44B
-5.85%2.43B
-6.00%2.43B
-3.84%10.28B
-2.25%2.52B
Deferred tax
21.71%-256M
69.52%-331M
-29.74%-711M
-20.09%-3.29B
-112.66%-1.33B
49.30%-327M
-38.87%-1.09B
20.23%-548M
-96.55%-2.74B
50.71%-624M
Other non cash items
4.58%365M
-10.34%130M
16,318.99%12.97B
16.86%1.21B
566.67%640M
3,590.00%349M
-60.06%145M
-86.59%79M
29.75%1.04B
166.67%96M
Change In working capital
486.60%1.71B
-39.47%-2.37B
114.56%198M
14.13%-1.91B
286.68%855M
77.44%291M
-8.07%-1.7B
-275.69%-1.36B
-76.76%-2.23B
-676.27%-458M
-Change in receivables
367.61%661M
-1,467.69%-1.02B
373.71%479M
-50.08%-995M
-379.25%-508M
63.35%-247M
90.28%-65M
-122.26%-175M
37.10%-663M
36.90%-106M
-Change in inventory
14.84%-218M
-1,306.25%-225M
22.70%-218M
-988.41%-751M
-380.49%-197M
-1,500.00%-256M
-23.08%-16M
-28,300.00%-282M
-630.77%-69M
67.97%-41M
-Change in payables and accrued expense
-6.18%-722M
3.59%-2.2B
12.98%1.21B
69.18%-405M
310.17%1.49B
-183.33%-680M
-87.21%-2.28B
25.41%1.07B
-60.64%-1.31B
-17,800.00%-708M
-Change in other working capital
34.74%1.99B
61.65%1.08B
35.51%-1.27B
229.51%237M
-81.86%72M
34.73%1.47B
102.13%665M
1.45%-1.97B
-130.60%-183M
70.39%397M
Cash from discontinued investing activities
Operating cash flow
17.68%5.59B
23.26%2.33B
-4.58%2.83B
6.08%13.86B
28.61%4.25B
28.86%4.75B
-16.54%1.89B
-22.09%2.97B
-19.38%13.07B
-18.51%3.31B
Investing cash flow
Cash flow from continuing investing activities
46.59%-219M
-300.91%-1.32B
-9,241.90%-19.62B
-116.10%-2.3B
-210.96%-1.35B
80.30%-410M
-13.84%-329M
-321.05%-210M
-97.40%-1.06B
202.49%1.21B
Capital expenditure reported
5.26%-324M
-1.16%-262M
-2.16%-284M
-8.14%-1.21B
4.62%-330M
-38.46%-342M
4.78%-259M
-9.88%-278M
-14.90%-1.12B
-8.13%-346M
Net business purchase and sale
-17.72%-93M
-11,130.00%-1.1B
-13,396.64%-19.81B
91.28%-260M
-190.91%-340M
97.40%-79M
103.64%10M
472.50%149M
-245.82%-2.98B
1,338.46%374M
Net investment purchase and sale
1,700.00%198M
157.50%46M
690.12%478M
-127.20%-826M
-157.05%-676M
-99.09%11M
-131.01%-80M
-120.88%-81M
134.16%3.04B
70.50%1.19B
Cash from discontinued investing activities
Investing cash flow
46.59%-219M
-300.91%-1.32B
-9,241.90%-19.62B
-116.10%-2.3B
-210.96%-1.35B
80.30%-410M
-13.84%-329M
-321.05%-210M
-97.40%-1.06B
202.49%1.21B
Financing cash flow
Cash flow from continuing financing activities
25.35%-3.85B
-85.14%-4.02B
580.13%14.64B
44.49%-9.42B
129.79%967M
-13.58%-5.16B
38.27%-2.17B
46.05%-3.05B
-4.55%-16.96B
18.17%-3.25B
Net issuance payments of debt
-26,420.00%-2.65B
-2,158.06%-2.8B
1,155.09%15.95B
108.59%456M
1,445.59%2.1B
99.65%-10M
95.55%-124M
-859.80%-1.51B
14.09%-5.31B
219.30%136M
Net common stock issuance
--0
--0
--0
35.57%-5.16B
--0
-583.76%-4B
---905M
95.00%-250M
-27.26%-8B
12.18%-2.42B
Cash dividends paid
-2.10%-1.22B
-1.67%-1.22B
-1.34%-1.21B
-2.37%-4.74B
-1.31%-1.16B
-3.21%-1.19B
-4.09%-1.2B
-0.93%-1.2B
-5.41%-4.63B
-4.19%-1.15B
Proceeds from stock option exercised by employees
-60.98%16M
-111.32%-6M
-5.43%-97M
-97.26%27M
-86.03%25M
-22.64%41M
-87.35%53M
-127.63%-92M
53.51%984M
--179M
Cash from discontinued financing activities
Financing cash flow
25.35%-3.85B
-85.14%-4.02B
580.13%14.64B
44.49%-9.42B
129.79%967M
-13.58%-5.16B
38.27%-2.17B
46.05%-3.05B
-4.55%-16.96B
18.17%-3.25B
Net cash flow
Beginning cash position
-25.27%6.3B
3.16%9.33B
23.53%11.52B
-34.86%9.33B
-4.89%7.57B
-23.13%8.43B
-28.07%9.05B
-34.86%9.33B
-4.39%14.32B
-42.67%7.96B
Current changes in cash
285.59%1.52B
-390.41%-3.02B
-637.93%-2.14B
143.34%2.15B
204.24%3.87B
72.11%-819M
60.27%-615M
83.39%-290M
-793.33%-4.96B
159.27%1.27B
Effect of exchange rate changes
302.63%77M
-175.00%-22M
-446.15%-45M
236.36%45M
-17.89%78M
42.42%-38M
88.73%-8M
44.44%13M
67.65%-33M
275.93%95M
End cash Position
4.29%7.89B
-25.27%6.3B
3.16%9.33B
23.53%11.52B
23.53%11.52B
-4.89%7.57B
-23.13%8.43B
-28.07%9.05B
-34.86%9.33B
-34.86%9.33B
Free cash flow
19.46%5.27B
26.78%2.06B
-5.27%2.55B
5.88%12.65B
32.50%3.92B
28.17%4.41B
-18.15%1.63B
-24.36%2.69B
-21.57%11.95B
-20.79%2.96B
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 17.68%5.59B23.26%2.33B-4.58%2.83B6.08%13.86B28.61%4.25B28.86%4.75B-16.54%1.89B-22.09%2.97B-19.38%13.07B-18.51%3.31B
Net income from continuing operations -37.18%1.22B-18.92%1.68B-625.28%-11.91B26.71%8.04B-12.99%1.76B20.27%1.93B45.35%2.08B76.70%2.27B-9.54%6.35B-14.63%2.03B
Operating gains losses -35.14%-300M-128.48%-377M-879.49%-382M-176.34%-724M26.96%-298M-14.43%-222M-298.80%-165M-115.18%-39M81.67%-262M-265.18%-408M
Depreciation and amortization 6.45%2.59B6.74%2.6B4.24%2.53B-5.02%9.76B-2.26%2.46B-5.91%2.44B-5.85%2.43B-6.00%2.43B-3.84%10.28B-2.25%2.52B
Deferred tax 21.71%-256M69.52%-331M-29.74%-711M-20.09%-3.29B-112.66%-1.33B49.30%-327M-38.87%-1.09B20.23%-548M-96.55%-2.74B50.71%-624M
Other non cash items 4.58%365M-10.34%130M16,318.99%12.97B16.86%1.21B566.67%640M3,590.00%349M-60.06%145M-86.59%79M29.75%1.04B166.67%96M
Change In working capital 486.60%1.71B-39.47%-2.37B114.56%198M14.13%-1.91B286.68%855M77.44%291M-8.07%-1.7B-275.69%-1.36B-76.76%-2.23B-676.27%-458M
-Change in receivables 367.61%661M-1,467.69%-1.02B373.71%479M-50.08%-995M-379.25%-508M63.35%-247M90.28%-65M-122.26%-175M37.10%-663M36.90%-106M
-Change in inventory 14.84%-218M-1,306.25%-225M22.70%-218M-988.41%-751M-380.49%-197M-1,500.00%-256M-23.08%-16M-28,300.00%-282M-630.77%-69M67.97%-41M
-Change in payables and accrued expense -6.18%-722M3.59%-2.2B12.98%1.21B69.18%-405M310.17%1.49B-183.33%-680M-87.21%-2.28B25.41%1.07B-60.64%-1.31B-17,800.00%-708M
-Change in other working capital 34.74%1.99B61.65%1.08B35.51%-1.27B229.51%237M-81.86%72M34.73%1.47B102.13%665M1.45%-1.97B-130.60%-183M70.39%397M
Cash from discontinued investing activities
Operating cash flow 17.68%5.59B23.26%2.33B-4.58%2.83B6.08%13.86B28.61%4.25B28.86%4.75B-16.54%1.89B-22.09%2.97B-19.38%13.07B-18.51%3.31B
Investing cash flow
Cash flow from continuing investing activities 46.59%-219M-300.91%-1.32B-9,241.90%-19.62B-116.10%-2.3B-210.96%-1.35B80.30%-410M-13.84%-329M-321.05%-210M-97.40%-1.06B202.49%1.21B
Capital expenditure reported 5.26%-324M-1.16%-262M-2.16%-284M-8.14%-1.21B4.62%-330M-38.46%-342M4.78%-259M-9.88%-278M-14.90%-1.12B-8.13%-346M
Net business purchase and sale -17.72%-93M-11,130.00%-1.1B-13,396.64%-19.81B91.28%-260M-190.91%-340M97.40%-79M103.64%10M472.50%149M-245.82%-2.98B1,338.46%374M
Net investment purchase and sale 1,700.00%198M157.50%46M690.12%478M-127.20%-826M-157.05%-676M-99.09%11M-131.01%-80M-120.88%-81M134.16%3.04B70.50%1.19B
Cash from discontinued investing activities
Investing cash flow 46.59%-219M-300.91%-1.32B-9,241.90%-19.62B-116.10%-2.3B-210.96%-1.35B80.30%-410M-13.84%-329M-321.05%-210M-97.40%-1.06B202.49%1.21B
Financing cash flow
Cash flow from continuing financing activities 25.35%-3.85B-85.14%-4.02B580.13%14.64B44.49%-9.42B129.79%967M-13.58%-5.16B38.27%-2.17B46.05%-3.05B-4.55%-16.96B18.17%-3.25B
Net issuance payments of debt -26,420.00%-2.65B-2,158.06%-2.8B1,155.09%15.95B108.59%456M1,445.59%2.1B99.65%-10M95.55%-124M-859.80%-1.51B14.09%-5.31B219.30%136M
Net common stock issuance --0--0--035.57%-5.16B--0-583.76%-4B---905M95.00%-250M-27.26%-8B12.18%-2.42B
Cash dividends paid -2.10%-1.22B-1.67%-1.22B-1.34%-1.21B-2.37%-4.74B-1.31%-1.16B-3.21%-1.19B-4.09%-1.2B-0.93%-1.2B-5.41%-4.63B-4.19%-1.15B
Proceeds from stock option exercised by employees -60.98%16M-111.32%-6M-5.43%-97M-97.26%27M-86.03%25M-22.64%41M-87.35%53M-127.63%-92M53.51%984M--179M
Cash from discontinued financing activities
Financing cash flow 25.35%-3.85B-85.14%-4.02B580.13%14.64B44.49%-9.42B129.79%967M-13.58%-5.16B38.27%-2.17B46.05%-3.05B-4.55%-16.96B18.17%-3.25B
Net cash flow
Beginning cash position -25.27%6.3B3.16%9.33B23.53%11.52B-34.86%9.33B-4.89%7.57B-23.13%8.43B-28.07%9.05B-34.86%9.33B-4.39%14.32B-42.67%7.96B
Current changes in cash 285.59%1.52B-390.41%-3.02B-637.93%-2.14B143.34%2.15B204.24%3.87B72.11%-819M60.27%-615M83.39%-290M-793.33%-4.96B159.27%1.27B
Effect of exchange rate changes 302.63%77M-175.00%-22M-446.15%-45M236.36%45M-17.89%78M42.42%-38M88.73%-8M44.44%13M67.65%-33M275.93%95M
End cash Position 4.29%7.89B-25.27%6.3B3.16%9.33B23.53%11.52B23.53%11.52B-4.89%7.57B-23.13%8.43B-28.07%9.05B-34.86%9.33B-34.86%9.33B
Free cash flow 19.46%5.27B26.78%2.06B-5.27%2.55B5.88%12.65B32.50%3.92B28.17%4.41B-18.15%1.63B-24.36%2.69B-21.57%11.95B-20.79%2.96B
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Concept Cancer Research
Cancer Research
Intraday+0.28%